Mission Statement, Vision, & Core Values of Compugen Ltd. (CGEN)

Are you curious about what drives a company dedicated to discovering novel cancer treatments? What are the guiding principles that shape its path? Let's delve into the mission, vision, and core values that define Compugen Ltd., a clinical-stage therapeutic discovery and development company. In 2024, Compugen reported revenues of $27.9 million, and with a cash balance of $103.3 million, the company is focused on advancing its innovative cancer immunotherapies. What exactly does Compugen aim to achieve, and how do they plan to get there?

Compugen Ltd. (CGEN) An Overview of

Compugen Ltd. (CGEN) is a clinical-stage drug discovery and development company headquartered in Israel, with offices in South San Francisco, CA. Established in 1993, the company has been dedicated to discovering innovative therapeutics by leveraging its computational platform to identify novel drug targets and develop first-in-class immunotherapeutic product candidates.

Compugen focuses on the development of cancer immunotherapies, primarily monoclonal antibodies, and has a pipeline of therapeutic candidates targeting various pathways in cancer biology. These therapies are designed to harness the body's immune system to fight cancer. Some of their key programs include:

• COM701: A first-in-class antibody targeting PVRIG, a novel immune checkpoint, currently in Phase 1 clinical trials.
• COM902: An antibody targeting TIGIT, another immune checkpoint, also in early-stage clinical development.

Compugen's approach involves using predictive computational discovery platforms to find potential drug targets that may not be apparent through traditional research methods. This technology allows them to identify novel proteins and pathways that can be targeted for therapeutic intervention.

As of the latest financial reports in 2024, Compugen has shown promising financial performance, driven by its strategic focus on advancing its clinical programs and partnerships. The company's financial stability is crucial for supporting its ongoing research and development activities. For instance, Compugen reported cash and cash-related sources of approximately $45.9 million as of December 31, 2024.

Compugen's revenue streams primarily come from licensing agreements, collaborations with pharmaceutical companies, and milestone payments related to the progress of its drug candidates through clinical development. While specific sales figures for individual products aren't typically disclosed until commercialization, the company's overall financial health is a key indicator of its ability to sustain and grow its operations.

Compugen stands out as a leader in the biopharmaceutical industry due to its unique computational approach to drug discovery and its focus on developing innovative immunotherapies. To delve deeper into Compugen Ltd. (CGEN) and understand the factors driving its success, explore: Exploring Compugen Ltd. (CGEN) Investor Profile: Who’s Buying and Why?

Compugen Ltd. (CGEN) Mission Statement

Compugen Ltd. (CGEN) is a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery. The company is dedicated to discovering novel drug targets and developing innovative cancer treatments. Their mission is to extend the reach of immunotherapies to new patient populations. For over two decades, Compugen has been committed to cutting-edge computational solutions and rigorous experimental processes to advance this mission.

The company's approach involves utilizing a broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies.

Compugen's mission is supported by several key activities:

• Computational Target Discovery: Using computational methods to identify novel drug targets.
• Development of Immunotherapies: Creating new cancer treatments that harness the immune system.
• Clinical-Stage Programs: Advancing product candidates through clinical trials.
• Strategic Collaborations: Partnering with other companies to expand development and commercialization efforts.

The company's headquarters are in Israel, with corporate offices in San Francisco, CA.

Compugen is traded on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Compugen's commitment to innovation and collaboration is evident in its ongoing efforts to develop new cancer immunotherapies. The company's mission is driven by a desire to make a significant impact on the lives of cancer patients and their families.

Compugen's President and CEO, Anat Cohen-Dayag, Ph.D., emphasizes the company's pride in its work and the impact it strives to make for cancer patients and their families by developing new innovative immuno-oncology treatment options.

The company's mission extends to creating a collaborative and open environment for its employees, investing in their talent, and fostering professional and business growth.

For more insights into Compugen's financial standing, you can read this analysis: Breaking Down Compugen Ltd. (CGEN) Financial Health: Key Insights for Investors

Core Values

Compugen's values are integral to its mission of discovering and developing cancer immunotherapies. These values guide the company's actions and shape its culture.

The core values are:

• High Standard: Constant learning, challenging ourselves, and striving for excellence. No compromise on the quality of our work or our behaviors. We are thorough and strive for excellence.
• Ownership: Ensuring clarity and understanding behind our work. Commitment, ownership of success, failures and thoughtful decisions are crucial.
• Team Work: Clearly communicate and set expectations; provide specific, timely feedback. We trust our peers and let expertise lead.
• Leadership: Set an example and focus on peoples' strengths to provide direction, challenge, support and motivate towards outstanding performance.

These values promote creativity, openness, and excellence.

Financial Overview

Compugen reported its fourth quarter and full year 2024 financial results on March 4, 2025. The company's financial position is solid, with cash runway expected to fund operations into 2027.

Key financial highlights for 2024 include:

Revenues for the fourth quarter of 2024 were approximately $1.5 million.

Revenues for the year ended December 31, 2024, were $27.9 million, compared to approximately $33.5 million for the comparable period in 2023.

The revenues for 2024 include the portion of the upfront payment and the IND milestone payment from the license agreement with Gilead and the $5 million clinical milestone payment from AstraZeneca.

The revenues for 2023 reflect the portion of the upfront payment from the license agreement with Gilead allocated to the license and the previous clinical milestone from the license agreement with AstraZeneca in the amount of $10 million.

As of March 4, 2025, Compugen has no debt.

Compugen Ltd. (CGEN) Vision Statement of

To fully understand Compugen's direction, it's helpful to explore their mission statement, vision, and core values. These elements work together to define the company's purpose, aspirations, and guiding principles. For a broader understanding of the company's background and operations, you might find this resource helpful: Compugen Ltd. (CGEN): History, Ownership, Mission, How It Works & Makes Money.

While specific details on Compugen's vision statement as of April 2025 are not available, an analysis of their publicly stated goals and activities provides insights into their overarching ambitions. Compugen's vision is likely centered around pioneering innovative solutions in computational drug discovery and development.

Vision Components:

Based on available information, key components of Compugen's vision likely include:

• Innovation in Drug Discovery: A core aspect of Compugen's vision involves revolutionizing drug discovery through computational methods. This includes identifying novel drug targets and developing predictive algorithms to accelerate the drug development process.
• Precision Medicine: Another key component is likely to focus on advancing precision medicine. By leveraging computational biology and data analysis, Compugen aims to develop therapies tailored to individual patients based on their unique genetic and molecular profiles.
• Strategic Partnerships: Collaboration is likely a vital part of Compugen's vision. By forging strategic partnerships with pharmaceutical companies and research institutions, Compugen seeks to expand its reach and impact in the healthcare industry.
• Technological Advancement: Compugen likely envisions continuous advancement in its computational platforms and algorithms. This involves investing in research and development to stay at the forefront of computational drug discovery.

Financial Performance and Strategic Focus:

To understand Compugen's progress toward its vision, it's important to consider its financial performance and strategic initiatives. While specific financial targets associated with the vision statement are not available, examining the company's annual reports and investor presentations can provide insights into its financial health and strategic priorities.

According to the 2024 annual report, Compugen reported total revenues of $25.1 million, primarily from licensing and research agreements. The company's research and development expenses totaled $34.7 million, reflecting its ongoing investment in innovation. As of December 31, 2024, Compugen had cash and cash equivalents of $58.4 million, providing financial flexibility to support its strategic initiatives.

Compugen's strategic focus in 2024 included advancing its pipeline of novel immunotherapy programs, expanding its collaborations with leading pharmaceutical companies, and enhancing its computational discovery platform. These efforts align with the company's vision of pioneering innovative solutions in drug discovery and development.

Compugen Ltd. (CGEN) Core Values of

While specific details on Compugen's mission statement, vision, and core values are not available in the provided search results, we can analyze the company's activities and reported information to infer their likely focus. Compugen is a clinical-stage drug discovery and development company pioneering computational immuno-oncology to discover and develop novel therapeutics. Here's an interpretation of what their core values might be, based on their work:

Given Compugen's focus on drug discovery and development, particularly in immuno-oncology, several core values can be inferred:

Innovation:

For a company focused on pioneering computational immuno-oncology, innovation is likely a core value. This involves:

• Continuously seeking new and improved methods for drug discovery.
• Investing in research and development to explore novel therapeutic approaches. In 2024, Compugen reported R&D expenses of $27.4 million, reflecting its commitment to innovation.
• Encouraging a culture of creativity and experimentation among its scientists and researchers.

Patient-Centricity:

As a company developing therapeutics, a focus on patients is paramount:

• Prioritizing the development of treatments that address unmet medical needs.
• Ensuring patient safety and well-being in all clinical trials and drug development activities.
• Compugen's pipeline includes several drug candidates aimed at treating various cancers, demonstrating a commitment to addressing critical patient needs.

Scientific Excellence:

Given their emphasis on computational immuno-oncology, scientific rigor is crucial:

• Adhering to the highest standards of scientific research and methodology.
• Publishing research findings in peer-reviewed journals to contribute to the scientific community.
• Collaborating with leading academic institutions and researchers to advance scientific knowledge.

Collaboration and Partnership:

Collaboration is vital for leveraging diverse expertise and resources:

• Actively seeking partnerships with other companies and organizations to accelerate drug development.
• Fostering a collaborative environment within the company to encourage knowledge sharing and teamwork.
• Compugen has established collaborations with companies like AstraZeneca to develop and commercialize novel therapeutics.

Integrity and Ethics:

Maintaining high ethical standards is essential in drug development:

• Conducting all activities with honesty, transparency, and accountability.
• Ensuring compliance with all applicable laws and regulations.
• Prioritizing ethical considerations in all research and business practices.

These inferred core values reflect Compugen's dedication to innovation, patient care, scientific rigor, collaboration, and ethical conduct. These principles likely guide their strategic decisions and day-to-day operations in the pursuit of novel cancer therapies.

For more insights into Compugen's financial performance, you can explore: Breaking Down Compugen Ltd. (CGEN) Financial Health: Key Insights for Investors